Fear of virologic failure is a major barrier to ensuring that people living with virally suppressed HIV are receiving the most optimal antiretroviral therapy (ART) regimen for them. Stream this Medical Minute to learn more about key guideline recommendations regarding ART switch and reassuring clinical data regarding efficacy, tolerability, and quality of life associated with switching a suppressive ART regimen. Topics covered include:Efficacy of switching to 2-drug oral ART: real-world evidenceReal-world analyses of virologic failure with switch to long-acting cabotegravir plus rilpivirinePatient selection to reduce risk of virologic failure with switch Regimen-specific switch considerationsPresenters:Dima Dandachi, MD, MPH, FIDSA, FACPAssociate Professor of MedicineDivision of Infectious DiseasesUniversity of MissouriMedical DirectorHIV Treatment and Prevention Program, MUHCMedical DirectorBoone County Public Health and Human ServicesColumbia, MissouriChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationQueen Mary University of LondonFaculty of Medicine and DentistryHonorary Consultant PhysicianBarts Health NHS TrustLondon, United KingdomLink to full program and accompanying slides:https://bit.ly/3KPN0xbGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related